Abbott (ABT) announced the U.S. FDA has approved the company’s Tendyne transcatheter mitral valve replacement system to treat people with mitral valve disease. This life-changing therapy is available for patients whose mitral valves are not functioning properly due to severe mitral annular calcification, a buildup of calcium within the ring-like structure that supports the mitral valve.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Unusually active option classes on open May 15th
- Abbott’s Libre technology reduces heart hospitalization in real-world study
- Positive Legal and Market Factors Justify Buy Rating for Abbott Laboratories
- ServiceNow, Enphase, Walgreens, Abbott, Amex: Insider Moves
- Abbott Laboratories Announces Executive Vice President’s Retirement